Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial

Although interleukin-23 has been implicated in the pathogenesis of asthma, in this randomized, controlled trial involving adults with severe asthma, inhibition of interleukin-23 signaling with the monoclonal antibody risankizumab resulted in worse asthma outcomes than placebo.

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 385; číslo 18; s. 1669 - 1679
Hlavní autori:	Brightling, Christopher E, Nair, Parameswaran, Cousins, David J, Louis, Renaud, Singh, Dave
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Boston Massachusetts Medical Society 28.10.2021 Massachussetts Medical Society
Predmet:	Adult Aged Allergy Anti-Asthmatic Agents Anti-Asthmatic Agents/adverse effects Anti-Asthmatic Agents/therapeutic use Antibodies, Monoclonal Antibodies, Monoclonal/adverse effects Antibodies, Monoclonal/therapeutic use Asthma Asthma/drug therapy Bronchoscopy Cell activation Clinical trials Critical Care Cytokines Cytotoxicity Disease control Disease Progression Double-Blind Method Double-blind studies Female Forced Expiratory Volume Forced Expiratory Volume/drug effects Gene expression General & internal medicine General Medicine Glucocorticoids Glucocorticoids/therapeutic use Human health sciences Humans Immunology Inflammation Interleukin 23 Interleukin-23 Subunit p19 Interleukin-23 Subunit p19/antagonists & inhibitors Lymphocytes T Male Medicine (all) Middle Aged Monoclonal antibodies Médecine générale & interne Natural killer cells Neutrophils Patients Placebos Pulmonary Respiratory tract Respiratory tract diseases risankizumab Safety Sciences de la santé humaine Sputum Statistical analysis Transcription activation Transcription factors Treatment Failure
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!